Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm - LARVOL DELTA

Impact of COVID-19 and Vaccination on Lower Urinary Tract Symptoms: Insights From a Prospective Cohort Study. (PubMed, Neurourol Urodyn) - "LUTS are prevalent in the acute phase of COVID-19, especially among women, but tend to improve within 3 months. Unexpectedly, full vaccination-especially with inactivated virus vaccines-was associated with increased odds of moderate to severe LUTS during hospitalization. Further studies are warranted to explore the underlying mechanisms and long-term implications."

Journal • Critical care • Infectious Disease • Novel Coronavirus Disease • Overactive Bladder • Respiratory Diseases • Urinary Incontinence • Urology

Safety of sinopharm COVID-19 vaccine in children and adolescents aged 5 to 18 years: a cohort event monitoring study. (PubMed, BMC Public Health) - "Sinopharm is a safe and well-tolerated vaccine option for children and adolescents and can be recommended for this population."

Journal • CNS Disorders • Epilepsy • Fatigue • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Pain

Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial. (PubMed, Vaccine) - P3 | "15 μg and 30 μg BNT162b2 boosters demonstrated comparable immunogenicity and favourable safety. 15 μg BNT162b2 booster doses may improve vaccine acceptability due to lower reactogenicity."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Manufacturing Technology and Effectiveness of Corona Vaccines: A Bibliometric Review. (PubMed, Arch Razi Inst) - "Furthermore, elasomeran, covilo, and tozinameran emerged as more recent than other keywords based on their temporal distribution. This study examines the documents published in one of the most reliable databases of vaccines against the novel strain of severe acute respiratory syndrome (SARS-CoV-2) from a bibliometric perspective. The findings of this study are expected to provide valuable insights and direction for future research initiatives, opportunities, and challenges in this field."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Serological Studies of IgG and IgM in Response to SARS-CoV-2 Vaccination in Erbil, Kurdistan-Iraq. (PubMed, Arch Razi Inst) - "The present study aims to provide a comparative analysis of the humoral immune responses elicited by BNT162b2 (mRNA-based), BBIBP-CorV (inactivated virus), and ChAdOx1 (dsDNA-recombinant) vaccines against the SARS-CoV-2 virus. The enhanced immune response observed with Sinopharm could be attributed to its nature as an inactivated subunit vaccine. The immunological reactions to the vaccines studied in the following studies have prompted a lot of issues about how they happen, and the study recommends more studies regarding the most effective vaccines among the Kurdish people in the Kurdistan Region of Iraq."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Impact of obstructive sleep apnea severity and treatment on COVID-19 vaccine-induced immune responses. (PubMed, J Thorac Dis) - "This study examines the effects of OSA on immune responses following the third dose of the inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac or BBIBP-CorV)...These findings highlight a severity-dependent impairment of vaccine-induced immune responses in untreated OSA participants, with evidence that PAP treatment may enhance vaccine efficacy. This study emphasizes the need to consider OSA severity and treatment when optimizing vaccination strategies for this population."

Journal • Infectious Disease • Novel Coronavirus Disease • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Seroprevalence and persistence of humoral immunity in response to SARS-CoV-2 vaccination and mild infection in Morocco: a cross-sectional study. (PubMed, Pan Afr Med J) - "This study evaluated the humoral immune response to the BBIBP-CorV and ChAdOx1 nCoV-19 vaccines in healthy donors with varying doses and infection histories. hybrid immunity, involving prior infection and full vaccination, offers enhanced and longer-lasting protection. These results support the need for targeted vaccination strategies to optimize immunity and reduce the risk of adverse outcomes, especially in high-risk populations."

Journal • Observational data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

False positive results in the Widal test in adults immunized with the Commirnaty (Pfizer-BioNtech) and BBIBP-CorV (Sinopharm) vaccines against COVID-19. (PubMed, Front Med (Lausanne)) - "Our results suggest misleading results of the Widal test in patients vaccinated against COVID-19, mainly in those vaccinated with Commirnaty. It is important to monitor and evaluate the results of routine immunological tests to ensure the quality of medical care."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique. (PubMed, Clin Infect Dis) - P2 | "The noninferiority criterion was met only in arm A1 versus A2. HePB regimens were safe and well tolerated."

Clinical • Head-to-Head • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial. (PubMed, EClinicalMedicine) - P3 | "This Phase 3, multicenter, international, randomized, active-controlled trial compared UB-612 as a third-dose heterologous booster to BNT162b2, ChAdOx1-S, or BBIBP-CorV homologous boosters in healthy subjects aged ≥16 years. In a pivotal Phase 3 study, UB-612 demonstrated the potential for broad use as a cross-platform heterologous booster, restoring protective immunity in adults previously vaccinated with mRNA, adenovirus-vectored, or inactivated virus-based COVID-19 vaccines. The study was co-funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity."

Journal • P3 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study. (PubMed, J Virol) - P4 | "Importantly, the older PLWH with low CD4+ T cell counts face considerable challenges in mounting an adequate immune response to vaccines, even after booster immunization. Our findings highlight the need for strategies to improve vaccine immunogenicity in PLWH with low immune responses, particularly among older individuals and those with low CD4+ T cell counts.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT05075070."

Journal • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • CD4

Exploring Immune Responses to SARS-CoV-2: Insights from Sinopharm (BBIBP-CorV)-Vaccinated Individuals in a Group of Venezuelan Admixed Volunteers. (PubMed, Biomedicines) - "An increase in the secretion of IFN-γ and granzyme B was also observed. It is suggested that the vaccine was able to generate a mild long-term memory against the SARS-CoV-2 virus in vaccinated adult individuals, independent of gender and BMI."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD14 • CD4 • CD40LG • CD8 • CD86 • GZMB • IFNG • LAMP2 • NKG2D

Evaluation of T cell immune memory response after BBIBP-CorV, gam-COVID-Vac, and heterologous gam-COVID-Vac /mRNA-1273 COVID-19 vaccination schemes against different SARS-CoV-2 variants. (PubMed, Vaccine) - "This study provides new data on effective humoral and cellular immune responses against the ancestral WT virus as well as the Gamma and Omicron variants. Moreover, memory CD4+ and CD8+ T cell responses remain protective, and the heterologous scheme may elicit stronger T cell responses against emerging variants."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine. (PubMed, Clin Infect Dis) - "We suggest that 1 dose of the BBIBP-CorV vaccine in seropositive individuals induced better antibodies response including against variant of concerns compared to that observed after 2 doses in seronegative individuals. A further homologous dose of the BBIBP-CorV vaccine, in those who are seropositive, does not improve the antibody response observed after the first dose."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Mechanistic Exploration of Yiqi Zengmian in Regulating the Microenvironment as an Immunopotentiator with the Beijing Bio-Institute of Biological Products Coronavirus Vaccine Based on Transcriptomics and Integrated Serum Pharmacochemistry. (PubMed, Pharmaceuticals (Basel)) - "This study aimed to investigate the immunopotentiating effects and mechanisms of YQZM in mice immunized with the BBIBP-CorV (Beijing Bio-Institute of Biological Products Coronavirus Vaccine)...Furthermore, molecular docking indicated that YQZM's primary active components exhibited strong binding affinity for critical proteins. YQZM effectively enhances vaccine-induced innate and adaptive immunity via a multi-component, multi-target mechanism, among which the TLR-JAK-STAT signaling pathway is a validated molecular target."

Journal • Infectious Disease • Novel Coronavirus Disease

Ethnic Comparisons of Spike-Specific CD4+ T Cells, Serological Responses, and Neutralizing Antibody Titers Against SARS-CoV-2 Variants. (PubMed, Vaccines (Basel)) - "Despite a small sample size and potential confounding by natural infections within our long-time-span sampling, our data suggest persistent cellular and humoral immunity 2 years after vaccination across ethnicities, with notable differences in T cell activation and cytokine profile. These preliminary observations highlight the need for larger, more detailed studies that consider intra-ethnic diversity and hybrid immunity to better understand ethnic differences in COVID-19 vaccine responses."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8 • IFNG • IL2 • TNFA

Adverse Effects Related to SARS-CoV-2 Vaccination in Patients With Rheumatic Diseases and Psoriasis From Argentina. (PubMed, J Clin Rheumatol) - "COVID-19 vaccines were generally well tolerated, with AE rates comparable to the general population. Heterologous regimens and vector-based and mRNA vaccines had higher AE incidence. These findings provide valuable safety data on vaccines used in Argentina and the region."

Adverse events • Journal • Dermatology • Immunology • Infectious Disease • Musculoskeletal Pain • Novel Coronavirus Disease • Psoriasis • Respiratory Diseases • Rheumatology

Low-dose intradermal mRNA-1273 boosting vaccine following BBiBP-CorV vaccination during the omicron pandemics. (PubMed, Vaccine) - "The 1/10 ID mRNA-1273 boosting after BBIBP-CorV priming was safe and induced above-threshold NAb against BA.2 and BA.4/5 for at least 12 weeks."

Journal • Infectious Disease • Novel Coronavirus Disease • Pain

COVID-19 vaccine effectiveness among healthcare workers during the Omicron period in the country of Georgia, January - June 2022. (PubMed, PLoS One) - "In Georgia, first booster dose VE against symptomatic SARS-CoV-2 infection among HCWs was moderately effective but waned very quickly during Omicron. Increased efforts to vaccinate priority groups in Georgia, such as healthcare workers, prior to periods of anticipated high COVID-19 incidence are essential."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Association between inactivated COVID-19 vaccine and semen quality among males recovered from omicron infection: a retrospective cohort study. (PubMed, Expert Rev Clin Immunol) - "We investigated associations between BBIBP-CorV vaccination and the semen quality in males recovering from SARS-CoV-2 infection...No significant results were found for long-term effect groups. Inactivated COVID-19 vaccination may protect against semen quality impairment among males recovering from SARS-CoV-2 Omicron infection within 90 days, especially in terms of semen volume and sperm progressive motility."

Journal • Retrospective data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Unexpected hypereosinophilia after Sinopharm vaccination: a case report. (PubMed, BMC Infect Dis) - "This case report underscores the potential for unexpected hematological adverse events following COVID-19 vaccination, even with inactivated vaccines. While a definitive causal relationship cannot be established, the temporal association between vaccination and symptom onset warrants further investigation. This case emphasizes the importance of continued surveillance for rare adverse events and additional research to elucidate the potential mechanisms underlying vaccine-associated eosinophilia."

Journal • Cardiovascular • Eosinophilia • Hematological Disorders • Hypereosinophilic Syndrome • Immunology • Infectious Disease • Novel Coronavirus Disease

COVID-19 inactivated booster vaccines elicit strong protection against SARS-CoV-2 wild-type and Omicron variant in patients with breast cancer. (PubMed, Front Med (Lausanne)) - "Blood samples from 211 breast cancer patients and 155 healthy controls were analyzed after one, two, or three doses of the inactivated SARS-CoV-2 vaccine...In particular, univariate and multivariate analyses revealed that the vaccination of breast cancer patients with CoronaVac resulted in significantly higher NAb inhibition rates against the SARS-CoV-2 wild-type virus than BBIBP-CorV...Vaccination-mediated NAb induction was affected by age, time > 6 months after vaccination, vaccine type, and cancer-targeted treatment. Therefore, the study results indicated an urgent need for caution and additional strategies to protect these patients."

Journal • Breast Cancer • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Solid Tumor

Efficacy and limitations of SARS-CoV-2 vaccines - A systematic review. (PubMed, Life Sci) - "Using information from 40 publications, including clinical trials and observational studies from 2019 to 2024, this review assesses the effectiveness, safety, and limitations of four major vaccines: Sinopharm (BBIBP-CorV), Moderna (mRNA-1273), Pfizer-BioNTech (BNT162b2), and CoronaVac...They showed considerable safety profiles, with mild side effects, but their low immunogenicity is concerning. This review emphasizes the importance of continuously evaluating vaccines in response to the evolving virus, essential for improving international immunization programs."

Journal • Review • Fatigue • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases

Ramsay-hunt-syndrome associated with unilateral parotitis following COVID-19 vaccine: a case report. (PubMed, Eur Arch Otorhinolaryngol) - "The possibility of VZV reactivation after COVID-19 vaccination is an important point and it should be noted that this reactivation might present in unusual clinical scenarios."

Journal • Herpes Zoster • Infectious Disease • Mumps • Novel Coronavirus Disease • Otorhinolaryngology • Varicella Zoster

Assessment of the factors affecting the clinical outcomes of infection and safety of vaccines against SARS-CoV-2 among Egyptian patients. (PubMed, BMC Infect Dis) - "Vaccination, particularly with BBIBP-CorV (Sinopharm), significantly reduces COVID-19 severity among Egyptians, despite various clinical presentations and hematological effects."

Clinical data • Journal • Retrospective data • Cardiovascular • Diabetes • Hematological Disorders • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Respiratory Diseases